Development of cancer immunotherapy using cancer-specific peptide based on genome analysis

基于基因组分析使用癌症特异性肽开发癌症免疫疗法

• 批准号: 17591459
• 负责人: SEKI Naohiko
• 金额: $ 2.24万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2006
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17591459/
• 关键词: Microarray; Gene; Chromosome; Immunotherapy; Lung cancer

Non-small cell lung cancer (NSCLC) is one of the leading causes of death. Diagnostic markers are required for choices of appropriate treatment. In this study, we examined WT1 expression levels in clinical specimens of non-small cell lung cancers (NSCLCs) and estimated the correlation between the WT1 gene expression levels and clinical statuses.WT1 expression levels of 50 NSCLCs (18 squamous cell carcinoma (SQ), 32 adenocarcinoma (AD)) were examined using quantitative real-time RT-PCR. A correlation between WT1 expression levels and clinical statuses was analyzed by statistical procedures.A wide range of WT1 expression levels was detected in NSCLSs by a quantitative real-time RT-PCR. A significant correlation between the WT1 expression and clinical status was revealed in SQ and AD. SQ patients expressed the WT1 were significantly nonmetastatic to lymph nodes (P=0.038).

非小细胞肺癌(NSCLC)是主要的死亡原因之一。诊断标记物是选择适当治疗方法所必需的。本研究检测了50例非小细胞肺癌(18例鳞癌，32例腺癌)标本中WT1基因的表达水平，并探讨了WT1基因表达水平与临床分期的关系。用统计学方法分析WT1的表达水平与临床状态的相关性。实时定量RT-PCR检测到WT1在非小细胞肺癌中的表达水平。在SQ和AD中，WT1的表达与临床状态显著相关。SQ组WT1阳性率显著高于非转移组(P=0.038)。